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Distinction of seropositive NMO
spectrum disorder and MS brain lesion
distribution
ABSTRACT
Objective: Neuromyelitis optica and its spectrum disorder (NMOSD) can present similarly to relapsing-
remittingmultiple sclerosis (RRMS). Using a quantitative lesionmapping approach, this research aimed
to identify differences inMRI brain lesion distribution between aquaporin-4 antibody–positive NMOSD
and RRMS, and to test their diagnostic potential.
Methods: Clinical brain MRI sequences for 44 patients with aquaporin-4 antibody–positive NMOSD
and 50 patients with RRMS were examined for the distribution and morphology of brain lesions. T2
lesion maps were created for each subject allowing the quantitative comparison of the 2 conditions
with lesion probability and voxel-wise analysis.
Results: Sixty-three percent of patients with NMOSD had brain lesions and of these 27% were diag-
nostic of multiple sclerosis. Patients with RRMSwere significantly more likely to have lesions adjacent
to the body of the lateral ventricle than patients with NMOSD. Direct comparison of the probability dis-
tributions and the morphologic attributes of the lesions in each group identified criteria of “at least
1 lesion adjacent to the body of the lateral ventricle and in the inferior temporal lobe; or the presence of
a subcortical U-fiber lesion; or a Dawson’s finger-type lesion,” which could distinguish patients with
multiple sclerosis from those with NMOSD with 92% sensitivity, 96% specificity, 98% positive pre-
dictive value, and 86% negative predictive value.
Conclusion: Careful inspection of the distribution andmorphology of MRI brain lesions can distinguish
RRMS and NMOSD. Neurology 2013;80:1330–1337
GLOSSARY
AQP4 5 aquaporin-4; AQP4-abs 5 aquaporin-4 antibodies; FLAIR 5 fluid-attenuated inversion recovery; FMRIB 5 Func-
tional Magnetic Resonance Imaging of the Brain; LETM 5 longitudinally extensive transverse myelitis; MNI 5 Montreal
Neurological Institute; MS 5 multiple sclerosis; NMO 5 neuromyelitis optica; NMOSD 5 neuromyelitis optica spectrum
disorder; RRMS 5 relapsing-remitting multiple sclerosis.
Neuromyelitis optica (NMO) is an inflammatory demyelinating condition of the CNS with a pre-
dilection for the optic nerves and spinal cord. NMO spectrum disorder (NMOSD) is a term used to
encompass NMO (with both optic neuritis and myelitis)1 and limited phenotypes such as recurrent
optic neuritis or myelitis. It is an autoimmune disorder, mediated in most cases by antibodies to the
aquaporin-4 (AQP4) water channel,2,3 and for the majority of patients serum AQP4 antibodies
(AQP4-abs) can be detected with an immunoassay.4 Making a definitive diagnosis of antibody-
negative NMOSD can be challenging because the more prevalent relapsing-remitting multiple
sclerosis (RRMS) can present similarly (e.g., with attacks of optic neuritis and myelitis).1,5,6 It is
vitally important to distinguish these 2 conditions: patients with NMOSD require long-term
immunosuppression to prevent devastating relapses, and disease-modifying treatments for RRMS
such as b-interferon can worsen NMOSD.7,8 Hence, we need other markers to help promptly
identify those who should be antibody tested, and to diagnose seronegative disease.
MRI is the best noninvasive tool we have for visualizing the pathology of neuroinflammatory dis-
eases in vivo, and has proven particularly useful in identifying patients with longitudinally extensive
transverse myelitis (LETM), which is highly suggestive of NMOSD.1 The objective of this study
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was to examine the utility of brain MRI in the
diagnosis of NMOSD, which would be partic-
ularly relevant to patients who present with a
spatially limited phenotype.9,10 A quantitative
probability analysis approach was used to docu-
ment the brain lesion distribution in a relatively
large cohort of AQP4-ab–positive patients with
NMOSD, comparing and contrasting with
RRMS.
METHODS The study dataset consisted of conventional MRI
examinations that were cross-sectional in nature.
Standard protocol approvals, registrations, and patient
consents. MRI scan and clinical data were collected in adherence to
regulations from the U.K. National Research Ethics Service. All
patients were consented for the use of their anonymized MRI exami-
nations and clinical details for research purposes.
Subjects. All subjects included in this study were older than 18
years, had available a good quality clinical (conventional) MRI brain
examination as assessed by a neuroradiologist (with the inclusion of
T1 weighting, T2 weighting, and fluid-attenuated inversion recovery
[FLAIR] sequences), and before the assessment of their MRI scans
were not known to have any other medical condition that may result
in hyperintense lesions on the T2/FLAIR sequences. MRI data were
contributed from the University of Oxford, University of Siena, Uni-
versity of Nottingham, and Cardiff University.
NMOSD cohort.Only subjects who were AQP4-ab positive (all
tested in Oxford with a cell-based assay technique)4,11,12 were
included. Twenty-eight fulfilled Wingerchuk criteria for NMO with
both optic neuritis and myelitis, 11 had relapsing LETM, 1 patient
had monophasic LETM, and 4 had relapsing optic neuritis. Of these
44 patients, 29 were identified to have T2 hyperintense lesions on
brain MRI. Three of these patients had a vascular-like lesion distri-
bution as determined by an experienced neuroradiologist without
knowledge of the diagnosis or the age of the patient. When
unblinded, it was apparent that these patients were older than the
remaining NMOSD cohort (with ages 72, 76, and 77 years), in
keeping with the likelihood of finding incidental vascular lesions.
These subjects were excluded from the group used to create the lesion
probability distribution. Their scans are shown in figure e-1 on the
Neurology® Web site at www.neurology.org.
RRMS cohort. Fifty subjects with the diagnosis RRMS who ful-
filled McDonald clinical criteria were included as a comparator
cohort.13 Among the 50 patients with multiple sclerosis (MS), 16
from Oxford who had consented to be tested for AQP4-abs were all
found to be negative. Because of the retrospective nature of the data
collection fromNottingham and Siena, these patients were not tested.
Table 1 summarizes the characteristics of the subjects including T2
lesion number and volume.
Lesion probability maps. Imaging data were analyzed using the
FMRIB Software Library of tools (University of Oxford, UK).14,15
For each subject, hyperintense T2 lesions were segmented manually
on an axial FLAIR image, in native space, with simultaneous refer-
ence to the T2 scan. This process was conducted independently on
every scan by 2 researchers, 1 with 3 years experience in T2 lesion
mapping (L.M.) and 1 neuroradiologist (R.M.). The FLAIR images
were then registered to the Montreal Neurological Institute (MNI)
2-mm standard space template using a nonlinear transformation
method (FNIRT [FMRIB’s nonlinear image registration tool]).16
The nonlinear transformation matrix was then applied to the respec-
tive lesion segmentation masks to transform them into the space of
the standard template. After transformation, the lesion masks were
thresholded at 50% and binarized again to avoid the volume increase
caused by the trilinear interpolation. They were then summed and
averaged for each subject group to create lesion probability maps. A
group-level comparison of lesion distribution was conducted using
the nonparametric permutation testing tool Randomise with cluster-
based thresholding and corrected for multiple comparisons.14
Description of lesion distribution in the NMOSD cohort.
T2 lesions were counted, and the lesion location and characteristics
were documented. Barkhof criteria for the dissemination of MS
lesions in space were applied to the unenhanced brain scans alone
(spinal cord scans not available).17 These criteria are a) at least 9
lesions on T2-weighted images, b) at least 3 periventricular lesions,
c) at least 1 juxtacortical lesion, and d) at least 1 infratentorial lesion.
The cutoff for positivity is 3 of 4 criteria. The NMOSD scans were
also examined for lesion morphology typical of MS, namely, juxta-
cortical lesions in the U-fiber (with a curved/s-shaped morphology)
and ovoid perpendicular lesions adjacent to the body of the lateral
ventricles often described as Dawson’s fingers.
RESULTS Cross-sectional examination of the brain
MRI scans from the cohort of 41 UK seropositive
NMOSD patients (excluding those with lesions consis-
tent with cerebrovascular disease) demonstrated T2
hyperintense lesions in 26 of 41 (63.4%). The lesion
probability distributions for the RRMS and NMOSD
patient groups are shown in figure 1, A and B. The
majority of lesions in the patients with NMOSD were
smaller in size and fewer in number compared with
patients with MS. The distribution throughout the
brain tissue was also widely variable: this is reflected in
the low probability of lesions occurring in the same
spatial location in more than 2 patients. The area of
highest probability of a lesion occurring in the NMOSD
group was within the frontal deep white matter (MNI
Table 1 Subject characteristics including T2 lesion volume and load
Diagnosis
NMOSD RRMS
No. of subjects 44 50
Age range (median), y 19–77 (47) 26–65 (42)
Sex 5 M, 39 F 16 M, 34 F
No. with positive AQP4 antibodies (%) 44 (100) 0/16 (0)a
Mean disease duration at time of MRI (SD), y 8.44 (6.4) 12.3 (6.8)
Mean EDSS score (SD) 4.9 (2.1) 1.83 (1.3)
No. with abnormal brain MRI 29 50
No. with vascular-like appearance 3 0
No. included in lesion probability maps 26 50
Mean T2 lesion volume (SD), mm3 4,045 (3,082) 11,870 (9,328)
No. of T2 lesions, range (median) 1–27 (13) 4–54 (20)
Abbreviations: AQP4 5 aquaporin-4; EDSS 5 Expanded Disability Status Scale; NMOSD 5
neuromyelitis optica spectrum disorder; RRMS 5 relapsing-remitting multiple sclerosis.
a Sixteen of the multiple sclerosis patients with available serum were tested for AQP4
antibodies.
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coordinate224 mm, 8 mm, 20 mm at a probability of
20%). Conversely, the most likely place for an RRMS
lesion to occur was adjacent to the posterior of the body
of the lateral ventricle in the parietal white matter (MNI
coordinate 30 mm, 250 mm, 14 mm), at a high
probability of 54% indicating greater lesion load and
coherence of lesion location among patients in the
RRMS group. Figure 1C shows a subtraction map in
which the average NMOSD lesion map has been sub-
tracted from the average RRMS lesion map to allow
Figure 1 Visual comparison of lesion probability distributions in neuromyelitis optica spectrum disorder (NMOSD) and relapsing-remitting
multiple sclerosis (RRMS)
(A) Lesion probability distribution for 50 subjects with RRMS. The color scale (from 0% to 55%) represents the minimum to maximum probability of a lesion
occurring in a particular spatial location. Montreal Neurological Institute (MNI) standard space template Z coordinate is shown in millimeters. (B) Lesion prob-
ability distribution for 26 subjects with aquaporin-4 antibody–positive NMOSD. The color scale (from 0% to 20%) represents the minimum to maximum
probability of a lesion occurring in a particular spatial location. MNI standard space Z coordinate is shown in millimeters. (C) Subtraction map in which the
average NMOSD lesion map has been subtracted from the average RRMS map to allow direct comparison of the lesion distributions. Red to yellow
represents where RRMS lesions are more likely than NMOSD, and light blue to dark blue where NMOSD lesions are more likely than RRMS. (D) Voxel-wise
comparison of lesion probability maps reveals that RRMS lesions are significantly more likely than NMOSD lesions to be adjacent to the body of the lateral
ventricle, shown here in red (corrected p , 0.05). MS 5 multiple sclerosis; NMO 5 neuromyelitis optica.
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direct comparison of the distributions. Lesions in
NMOSD and RRMS are found throughout the supra-
and infratentorial white and gray matter. However, dis-
tinguishing features of note were more NMOSD lesions
in the medulla oblongata, whereas in the RRMS group,
more lesions were noted within the cerebellum, border-
ing the lateral aspect of the body of the lateral ventricles
(including within the periventricular gray matter) and
in the temporal lobes. Both conditions were associ-
ated with lesions in the corpus callosum. Figure 1D
shows the voxel-wise permutation-testing comparison
of the lesion distributions in each group. RRMS lesions
are significantly more likely than NMOSD lesions to be
adjacent to the body of the lateral ventricle (corrected
p , 0.05). The lesional region with the greatest likeli-
hood to be within the NMOSD and not the RRMS
group was adjacent to the fourth ventricle within the
pons. This did not reach statistical significance (cor-
rected p 5 0.35) because of the lower lesion load in
NMOSD.
The proportion of NMOSD T2 lesions occurring
in specific spatial locations within the brain is shown
in table 2. Examples of these patterns are shown in
figure 2. Of note, the most common distribution for
patients with NMOSD is supratentorial deep white
matter lesions.
Seven of 26 patients with NMOSD who had brain
lesions, or 15.9% of all patients with NMOSD, fulfilled
Barkhof criteria for the dissemination of RRMS lesions
in space,17 based on unenhanced brain MRI alone.
There are important differences, however, in the mor-
phology of the lesions. None of the patients with
NMOSD had juxtacortical T2 hyperintensities with
morphology suggestive of location in the U-fiber, unlike
the RRMS cohort. It is also of note that lesions adjacent
to the lateral ventricles in NMOSD tend to be located at
the anterior and posterior horns (figure 2A), and that no
patients had ovoid lesions in a perpendicular alignment
(Dawson’s fingers).
CSF examination had been performed in 34 of the
patients with NMOSD. Of those, 9 tested positive for
oligoclonal bands. Of the 7 patients who fulfilled Bar-
khof criteria, 1 tested positive for oligoclonal bands;
therefore, there is no increased likelihood within this
subgroup. The clinical phenotypes of this group of pa-
tients were 5 with NMO as described by the 2006
Wingerchuk criteria,1 and 2 with relapsing LETM.
Within the NMOSD cohort, colocalized T1 hypo-
intensity was found in 0% to 83.3% of T2 lesions
(38% of all T2 lesions). This compares with 25% to
95% of MS lesions (53.4% of all T2 lesions).
Formulation of criteria for the separation of RRMS and
NMOSD. Using the findings summarized above, we
were able to hypothesize that RRMS could be distin-
guished from NMOSD on the basis of T2 brain lesion
distribution. We tested criteria of having at least 1 lesion
adjacent to the body of the lateral ventricle and at least
1 lesion in the inferior temporal lobe for the identifica-
tion of RRMS. This was able to identify RRMS with
78% sensitivity, 96.2% specificity, 97.5% positive pred-
icative value, and 69.4% negative predictive value
Table 2 Lesion location for 26 patients with
NMOSD who tested positive for
aquaporin-4 antibodies
Lesion location Percentage
Supratentorial 92.8
Adjacent to lateral ventricles 11.9
Large hemispheric lesion 0.9
Deep white matter 48.1
Subcortical 30.7
Deep gray matter 1.2
Infratentorial 7.2
Brainstem 6.3
Cerebellum 0.9
Table 3 Numbers of subjects fulfilling and the sensitivity and specificity of each criterion/combination of criteria for the separation of RRMS
from NMOSD
No. of
subjects
Criterion 1: Lesion
adjacent to the body
of a lateral ventricle
Criterion 2:
Inferior temporal
lobe lesion
Criterion 3:
Criteria 1 and
2 satisfied
Criterion 4: U-fiber
or Dawson’s
finger–type lesion
Criterion 3 or
4 satisfied
NMOSD, n 26 6 5 1 0 1
RRMS, n 50 46 40 39 41 46
Sensitivity of distinguishing
RRMS from NMOSD, %
— 92 80 78 82 92
Specificity of distinguishing
RRMS from NMOSD, %
— 76.9 80.8 96.2 100 96.2
Positive predictive value, % — 88.5 88.9 97.5 100 97.9
Negative predictive value, % — 83.3 67.7 69.4 74 86.2
Abbreviations: NMOSD 5 neuromyelitis optica spectrum disorder; RRMS 5 relapsing-remitting multiple sclerosis.
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(table 3). Of the patients with RRMS who did not fulfill
both criteria, 7 of 11 had either an ovoid lesion perpen-
dicular to a lateral ventricle or a subcortical lesion with
morphology suggestive of location in the U-fiber (exam-
ples of these lesions are shown in figure e-2). Adding this
as a further criterion resulted in a 92% sensitivity,
96.2% specificity, 97.9% positive predictive value,
and 86.2% negative predictive value. A flow diagram
summarizing the way in which these criteria should be
applied is given in figure 3.
The definition of an NMO typical brain lesion (e.g.,
a lesion that occurs in the periependymal brain tissue or
hypothalamus)18 is relatively subjective and RRMS
lesions can also occur in these locations. The criteria
are designed to be used objectively by nonexperts and
therefore the term “NMO typical” has been avoided in
this study. However, we investigated whether a lesion
adjacent to the fourth ventricle could help to correctly
identify NMOSD. This did not improve the accuracy of
the criteria—in fact, only 9% of patients with NMOSD
Figure 2 Neuromyelitis optica spectrum disorder (NMOSD) lesions
Examples of NMOSD (all with positive aquaporin-4 antibody) fluid-attenuated inversion recovery scans showing lesions in
locations corresponding to table 2. (A) Adjacent to the lateral ventricle. (B) Nonspecific white matter. (C) Large hemispheric
lesion that had been biopsied. (D) Thalamic. (E) Juxtacortical. (F) Pontine. (G) Medullar oblongata. (H) Cerebellar. (I) Adjacent
to the fourth ventricle.
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who were AQP4-ab positive in this study had lesions
that may be considered NMO typical, consistent with
previous literature.19
DISCUSSION By applying a quantitative lesion
probability mapping approach to a large cohort of
AQP4-ab–positive NMOSD patients and RRMS
patients, we have been able to identify important differ-
ences in brain lesion distribution. Consequently, we
propose criteria to aid the diagnostic separation of
RRMS and NMOSD. These are at least 1 lesion on a
T2-weighted scan (which could be T2 spin echo or
fluid-attenuated imaging) in both the inferior temporal
lobe and adjacent to the body of the lateral ventricle, or
either a subcortical lesion with a U-fiber–type morphol-
ogy (s-shaped or curved) or an ovoid lesion perpendic-
ular to the lateral ventricle (Dawson’s fingers). This
identifies RRMS with 92% sensitivity and 96.2% spec-
ificity. The criteria therefore are very useful in making a
definitive diagnosis of RRMS when faced with a patient
with a borderline clinical presentation. If a patient does
not fulfill the criteria, this is suggestive but not diagnos-
tic of NMOSD and can be used in conjunction with
evidence from clinical assessment and other investiga-
tions such as CSF examination.
The criteria have been formed from an approxi-
mately 2:1 RRMS:NMOSD cohort. In our clinical
experience, this is a similar mix to those patients present-
ing with an RRMS/NMOSD overlap syndrome for
diagnosis. Increasing the proportion of NMOSD
patients would increase the accuracy and vice versa.
Hence, these are not suitable for screening an unselected
population of patients with MS. Of note, the criteria’s
ability to separate the 2 conditions is strong despite only
using NMOSD patients who have T2 lesions—a nor-
mal brain scan (in this cohort found in 34% of subjects)
is highly in favor of a diagnosis of NMOSD over
RRMS, as previously reported.1,5,19
We have shown that in NMOSD patients with
brain lesions, the distribution is variable and can
be disseminated throughout the cerebral gray and
white matter, as can be found in patients with MS.
Figure 3 Flow diagram summarizing application of criteria for the separation of relapsing-remitting multiple
sclerosis (RRMS) and neuromyelitis optica spectrum disorder (NMOSD)
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Consequently, 27% of NMOSD patients with brain
lesions fulfilled Barkhof criteria for the dissemina-
tion of MS lesions in space,17 and it is likely that the
addition of gadolinium-enhanced scans and spinal cord
imaging would have increased the proportion further,
so careful localization and consideration of the mor-
phology is important. None of the patients with
NMOSD had ovoid lesions in a perpendicular align-
ment to the lateral ventricles, and none had U-fiber–
shaped subcortical lesions.
The probability distribution map for our cohort
of patients with RRMS, showing that lesions are
most likely to occur adjacent to the lateral ventricles,
is consistent with previous findings.20,21 Also consis-
tent with previous case studies is our observation
that the most common location for an NMOSD
lesion is deep white matter.19,22,23 We also show that
medullary lesions are more common in NMOSD
than RRMS. These lesions may be contiguous with
a high cervical spinal cord lesion.
Three patients with NMOSD were excluded
because they had brain lesions compatible with vas-
cular pathology. They are acknowledged in this
report (figure e-1) to highlight that one must be
aware of possible comorbid causes of brainMRI abnor-
malities because NMOSD can present for the first time
in older people. Deep white matter lesions docu-
mented in the 26 patients with NMOSD used in
our lesion distribution analysis were found in patients
with an age range of 19 to 66 years, indicating that they
are unlikely to be due to a non-AQP4-ab–mediated
vascular cause.
To truly characterize the lesion distribution of
patients with NMOSD, it has been necessary to on-
ly include AQP4-ab–positive patients in our study
cohort, i.e., so that the diagnosis is not in doubt.
The RRMS patient data included was collected ret-
rospectively and therefore it was not possible to test
all of them for AQP4-abs. Sixteen of the 50 patients
with RRMS were tested using the Oxford cell-based
assay and found to be negative. During previous
validation of this assay, no patients with MS were
found to have AQP4-abs.4,12
The next stage of this work is to validate our
proposed criteria in an independent cohort and to
prospectively test their utility in the management of
antibody-negative patients who present with an opti-
cospinal syndrome.
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Comment:
MRI criteria distinguishing seropositive NMO spectrum disorder
from MS
The authors have made a quantitative analysis of the shape and distribution of
focal T2 white matter lesions by means of lesion probability maps and voxel-wise
analysis to distinguish neuromyelitis optica spectrum disorders (NMOSD) frommul-
tiple sclerosis (MS). Forty-four patients with aquaporin-4 (AQP4) antibody-positive
NMOSD and 50 patients with relapsing-remitting MS (RRMS) were enrolled,
though 3 of the patients with NMOSD with apparent ischemic brain lesions were
excluded from the analyses. Sixty-three percent of patients with NMOSD and all
the patients with RRMS had brain lesions, with 27% of the patients with NMOSD
fulfilling Barkhof criteria for dissemination in space. The authors found that the cri-
teria of at least one T2 lesion in both the inferior temporal lobe white matter and
adjacent to the body of the lateral ventricle or either a juxtacortical lesion with
U-fiber type morphology or an ovoid lesion perpendicular to the lateral ventricle
(Dawson finger) were able to distinguish RRMS fromNMOSDwith high accuracy.1
RRMS and NMOSD can present with clinical, CSF, and radiologic similari-
ties2 and it may be difficult to distinguish these 2 entities to establish the more
suitable treatment. Because a proportion of patients with NMOSD have a nega-
tive antibody test, it is important to identify other markers to differentiate both
conditions.3
This study provides new criteria based on the shape and distribution of focal
lesions on conventional brain MRI that seem to differentiate NMOSD from
RRMS with high accuracy, which can be easily incorporated into the clinical
practice. However, only patients with NMOSD with positive AQP4 antibody
were included and the added diagnostic value of assessing the spinal cord was
not evaluated. Therefore, it would be important to test these criteria in an inde-
pendent cohort of patients with NMOSD and patients with RRMS, and in a
cohort of seronegative patients with NMOSD, as well as to evaluate the potential
contribution of adding MRI spinal cord features in the diagnostic scheme.
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